Debate over the cardiovascular effects of COX-2 inhibitors has raged for more than a year since a special communication was published in JAMA last August suggesting an increase in cardiovascular events with rofecoxib (Vioxx). Now a large retrospect, the cohort study from the Tennessee Medicaid program seems to confirm the prothrombotic effects of rofecoxib, at least in high dose.
Between 1973 and 1980, the American Cancer Society and the National Cancer Institute conducted the Breast Cancer Detection Demonstration Project (BCDDP). More than one quarter of a million women were involved in this study.
There are a number of significant advancements in pain management that will impact your clinical practice, including more frequent use of patient-controlled analgesia and increased use of conscious sedation.
